Last reviewed 2026-04-20 · How we verify

SERD

Serd, developed by Fudan University, is a marketed small molecule for the treatment of attention deficit hyperactivity disorder (ADHD). The drug's key strength lies in its unique mechanism of action, which interacts with specific biological pathways to produce a therapeutic effect. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Approved indications

• Attention deficit hyperactivity disorder

Common side effects

• Decreased appetite
• Insomnia
• Nausea
• Vomiting
• Dyspepsia
• Abdominal pain
• Weight decreased
• Anxiety
• Dizziness
• Irritability
• Affect lability
• Tachycardia

Serious adverse events

• Pancytopenia
• Thrombocytopenia
• Thrombocytopenic purpura
• Angina pectoris
• Bradycardia

Key clinical trials

• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer (PHASE1,PHASE2)
• Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
• Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (PHASE2)
• DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment (PHASE2)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (PHASE3)
• Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (PHASE3)
• Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (PHASE3)
• Ph 2 Elacestrant in ER Positive Uterine Sarcomas (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.